Compare NCLH & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NCLH | HALO |
|---|---|---|
| Founded | 1966 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.7B | 7.4B |
| IPO Year | 2013 | N/A |
| Metric | NCLH | HALO |
|---|---|---|
| Price | $24.44 | $75.09 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 18 | 12 |
| Target Price | $28.11 | ★ $73.33 |
| AVG Volume (30 Days) | ★ 16.5M | 2.2M |
| Earning Date | 02-26-2026 | 02-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 11.76 | ★ 56.68 |
| EPS | 1.40 | ★ 4.74 |
| Revenue | ★ $9,692,558,000.00 | $1,242,852,000.00 |
| Revenue This Year | $6.85 | $34.83 |
| Revenue Next Year | $10.26 | $24.84 |
| P/E Ratio | $17.03 | ★ $15.44 |
| Revenue Growth | 3.59 | ★ 31.19 |
| 52 Week Low | $14.21 | $47.50 |
| 52 Week High | $29.29 | $79.50 |
| Indicator | NCLH | HALO |
|---|---|---|
| Relative Strength Index (RSI) | 70.89 | 72.04 |
| Support Level | $21.96 | $67.02 |
| Resistance Level | $24.32 | $69.48 |
| Average True Range (ATR) | 0.86 | 1.85 |
| MACD | 0.13 | 0.92 |
| Stochastic Oscillator | 99.83 | 91.07 |
Norwegian Cruise Line is the world's third-largest publicly traded cruise company by berths (around 71,000). It operates 34 ships across three brands—Norwegian, Oceania, and Regent Seven Seas—offering both freestyle and luxury cruising. The company redeployed its entire fleet as of May 2022. With 13 passenger vessels on order among its brands through 2036, representing 38,400 incremental berths, Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sails to around 700 global destinations.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.